Amylyx Pharmaceuticals (AMLX) Competitors $5.43 -0.09 (-1.63%) Closing price 04:00 PM EasternExtended Trading$5.33 -0.10 (-1.84%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. CGON, TARS, GLPG, APGE, RXRX, TWST, BEAM, ARQT, AGIO, and SDGRShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include CG Oncology (CGON), Tarsus Pharmaceuticals (TARS), Galapagos (GLPG), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. CG Oncology Tarsus Pharmaceuticals Galapagos Apogee Therapeutics Recursion Pharmaceuticals Twist Bioscience Beam Therapeutics Arcutis Biotherapeutics Agios Pharmaceuticals Schrödinger CG Oncology (NASDAQ:CGON) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Which has more volatility & risk, CGON or AMLX? CG Oncology has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500. Which has stronger earnings and valuation, CGON or AMLX? Amylyx Pharmaceuticals has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$662K3,019.06-$48.61M-$1.51-17.36Amylyx Pharmaceuticals-$1.27M-380.53$49.27M-$3.11-1.75 Is CGON or AMLX more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. CG Oncology's return on equity of -18.97% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Amylyx Pharmaceuticals N/A -36.97%-29.61% Do institutionals & insiders have more ownership in CGON or AMLX? 26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 7.4% of CG Oncology shares are owned by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CGON or AMLX? Amylyx Pharmaceuticals received 10 more outperform votes than CG Oncology when rated by MarketBeat users. However, 90.63% of users gave CG Oncology an outperform vote while only 69.64% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes2990.63% Underperform Votes39.38%Amylyx PharmaceuticalsOutperform Votes3969.64% Underperform Votes1730.36% Do analysts rate CGON or AMLX? CG Oncology currently has a consensus price target of $58.22, suggesting a potential upside of 122.05%. Amylyx Pharmaceuticals has a consensus price target of $9.83, suggesting a potential upside of 81.09%. Given CG Oncology's higher probable upside, equities analysts plainly believe CG Oncology is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Amylyx Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Does the media prefer CGON or AMLX? In the previous week, CG Oncology had 10 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 18 mentions for CG Oncology and 8 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.89 beat CG Oncology's score of 0.66 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCG Oncology beats Amylyx Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$484.04M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-1.428.9226.8419.71Price / Sales-380.53250.96391.39116.98Price / Cash5.5165.8538.2534.62Price / Book0.856.466.794.50Net Income$49.27M$143.98M$3.23B$248.18M7 Day Performance24.83%3.04%4.07%1.14%1 Month Performance28.37%7.44%12.52%15.18%1 Year Performance201.67%-2.46%16.83%6.55% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.4725 of 5 stars$5.43-1.6%$9.83+81.1%+200.0%$484.04M$-1,272,000.00-1.42200CGONCG Oncology2.2351 of 5 stars$24.86-2.2%$58.22+134.2%-10.7%$1.89B$662,000.00-16.4661Analyst ForecastTARSTarsus Pharmaceuticals3.3008 of 5 stars$45.01+3.0%$66.33+47.4%+15.9%$1.89B$233.67M-11.8150Positive NewsGLPGGalapagos0.4867 of 5 stars$27.91+0.6%$25.33-9.2%-1.0%$1.84B$288.19M0.001,310News CoveragePositive NewsAPGEApogee Therapeutics2.1534 of 5 stars$39.91-1.7%$94.60+137.0%-23.0%$1.84BN/A-16.4991Positive NewsGap DownRXRXRecursion Pharmaceuticals2.4174 of 5 stars$4.51-1.1%$7.60+68.5%-53.5%$1.83B$59.82M-2.95400Positive NewsGap DownTWSTTwist Bioscience4.3119 of 5 stars$30.39-1.7%$50.40+65.8%-31.1%$1.82B$347.68M-8.99990Positive NewsBEAMBeam Therapeutics3.1396 of 5 stars$17.66-1.3%$48.75+176.0%-28.5%$1.78B$63.58M-10.03510Positive NewsARQTArcutis Biotherapeutics2.779 of 5 stars$14.64+3.8%$18.80+28.4%+55.2%$1.75B$212.82M-8.18150News CoveragePositive NewsInsider TradeAGIOAgios Pharmaceuticals4.0346 of 5 stars$29.84+2.3%$56.00+87.7%-9.1%$1.73B$37.04M2.63390Positive NewsAnalyst DowngradeSDGRSchrödinger2.9603 of 5 stars$23.56-0.1%$32.80+39.2%-4.7%$1.72B$230.49M-10.07790News CoveragePositive News Related Companies and Tools Related Companies CG Oncology Competitors Tarsus Pharmaceuticals Competitors Galapagos Competitors Apogee Therapeutics Competitors Recursion Pharmaceuticals Competitors Twist Bioscience Competitors Beam Therapeutics Competitors Arcutis Biotherapeutics Competitors Agios Pharmaceuticals Competitors Schrödinger Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMLX Stock Free AMLX Stock Alerts